124 related articles for article (PubMed ID: 35843111)
1. Comparison of ceftazidime-avibactam susceptibility testing methods against OXA-48-like carrying Klebsiella blood stream isolates.
Isler B; Vatansever C; Özer B; Çınar G; Aslan AT; Stewart A; Simos P; Falconer C; Bauer MJ; Forde B; Harris P; Şimşek F; Tülek N; Demirkaya H; Menekşe Ş; Akalin H; Balkan İİ; Aydın M; Tigen ET; Demir SK; Kapmaz M; Keske Ş; Doğan Ö; Arabacı Ç; Yağcı S; Hazırolan G; Bakır VO; Gönen M; Saltoğlu N; Azap A; Azap Ö; Akova M; Ergönül Ö; Paterson DL; Can F
Diagn Microbiol Infect Dis; 2022 Sep; 104(1):115745. PubMed ID: 35843111
[TBL] [Abstract][Full Text] [Related]
2. Will ceftazidime/avibactam plus aztreonam be effective for NDM and OXA-48-Like producing organisms: Lessons learnt from
Pragasam AK; Veeraraghavan B; Shankar BA; Bakthavatchalam YD; Mathuram A; George B; Chacko B; Korula P; Anandan S
Indian J Med Microbiol; 2019; 37(1):34-41. PubMed ID: 31424008
[TBL] [Abstract][Full Text] [Related]
3. The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant
Nasomsong W; Nulsopapon P; Changpradub D; Pongchaidecha M; Pungcharoenkijkul S; Juntanawiwat P; Simsiriporn W; Santimaleeworagun W
Drug Des Devel Ther; 2021; 15():3095-3104. PubMed ID: 34295150
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Ceftazidime-Avibactam 30/20-μg Disk, Etest versus Broth Microdilution Results When Tested against
Han R; Yang X; Yang Y; Guo Y; Yin D; Ding L; Wu S; Zhu D; Hu F
Microbiol Spectr; 2022 Feb; 10(1):e0109221. PubMed ID: 35019685
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of Ceftazidime-Avibactam and its comparators against Carbapenem resistant Enterobacterales collected across India: results from ATLAS surveillance 2018 to 2019.
Bakthavatchalam YD; Routray A; Mane A; Kamat S; Gupta A; Bari AK; Rohit A; Poojary A; Mukherjee DN; Sethuraman N; Munshi N; Shah S; Balaji V; Gupta Y
Diagn Microbiol Infect Dis; 2022 May; 103(1):115652. PubMed ID: 35255290
[TBL] [Abstract][Full Text] [Related]
6. Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.
Dupont H; Gaillot O; Goetgheluck AS; Plassart C; Emond JP; Lecuru M; Gaillard N; Derdouri S; Lemaire B; Girard de Courtilles M; Cattoir V; Mammeri H
Antimicrob Agents Chemother; 2016 Jan; 60(1):215-21. PubMed ID: 26482307
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Etest and broth microdilution for evaluating the susceptibility of Staphylococcus aureus and Streptococcus pneumoniae to ceftaroline and of carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa to ceftazidime/avibactam.
Huang YT; Kuo YW; Teng LJ; Liao CH; Hsueh PR
J Glob Antimicrob Resist; 2021 Sep; 26():301-307. PubMed ID: 34303027
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Aktaş Z; Kayacan C; Oncul O
Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
[TBL] [Abstract][Full Text] [Related]
10.
Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
[No Abstract] [Full Text] [Related]
11. Performance of ceftazidime/avibactam susceptibility testing methods against clinically relevant Gram-negative organisms.
Wenzler E; Lee M; Wu TJ; Meyer KA; Shields RK; Nguyen MH; Clancy CJ; Humphries RM; Harrington AT
J Antimicrob Chemother; 2019 Mar; 74(3):633-638. PubMed ID: 30534964
[TBL] [Abstract][Full Text] [Related]
12. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I
Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
[TBL] [Abstract][Full Text] [Related]
13.
Yu F; Lv J; Niu S; Du H; Tang YW; Bonomo RA; Kreiswirth BN; Chen L
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891605
[TBL] [Abstract][Full Text] [Related]
14. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE
Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206
[TBL] [Abstract][Full Text] [Related]
15. [In Vitro Activity of Ceftazidime-avibactam and Colistin Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates].
Hoşbul T; Aydoğan CN; Kaya S; Bedir O; Gümral R; Albay A
Mikrobiyol Bul; 2022 Apr; 56(2):218-229. PubMed ID: 35477226
[TBL] [Abstract][Full Text] [Related]
16. Changing Characteristics and
Mavroidi A; Katsiari M; Likousi S; Palla E; Roussou Z; Nikolaou C; Mathas C; Merkouri E; Platsouka ED
Microb Drug Resist; 2020 Jan; 26(1):28-37. PubMed ID: 31386596
[TBL] [Abstract][Full Text] [Related]
17. Comparison of carbapenem minimum inhibitory concentrations of Oxacillin-48-like Klebsiella pneumoniae by Sensititre, Vitek 2, MicroScan, and Etest.
Nana T; Perovic O; Chibabhai V
Clin Microbiol Infect; 2022 Dec; 28(12):1650.e1-1650.e5. PubMed ID: 35811020
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects.
Bianco G; Boattini M; Comini S; Iannaccone M; Bondi A; Cavallo R; Costa C
Eur J Clin Microbiol Infect Dis; 2022 Jan; 41(1):63-70. PubMed ID: 34462816
[TBL] [Abstract][Full Text] [Related]
19. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains.
Castanheira M; Mills JC; Costello SE; Jones RN; Sader HS
Antimicrob Agents Chemother; 2015; 59(6):3509-17. PubMed ID: 25845862
[TBL] [Abstract][Full Text] [Related]
20. Results of the Italian infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-IT): activity of ceftazidime/avibactam against Enterobacterales isolated from urine.
Giani T; Antonelli A; Sennati S; Di Pilato V; Chiarelli A; Cannatelli A; Gatsch C; Luzzaro F; Spanu T; Stefani S; Rossolini GM
J Antimicrob Chemother; 2020 Apr; 75(4):979-983. PubMed ID: 31958125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
